Posted on 524
Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC
TM) platform, announced today the members of its strategic advisory board, which bring a range of expertise to the company including corporate strategy, clinical development, cellular biology, and cancer therapeutics.
“Shasqi has made important progress during the last year with the initiation of our phase 1 clinical trial of SQ3370 and the advancement of our CAPAC drug development platform we’re preparing for the next phase of our growth,” said José M. Mejía Oneto, M.D., Ph.D., Founder and CEO of Shasqi. “We’ve deliberately selected and cultivated a team of strategic advisors with the skills, expertise and experience to help us navigate through the opportunities ahead of us and, ultimately, position us to benefit as many peop